Related Experiment Video

Updated: Aug 30, 2026

A Method of Nodose Ganglia Injection in Sprague-Dawley Rat
09:28

A Method of Nodose Ganglia Injection in Sprague-Dawley Rat

Published on: November 25, 2014

Effects of chronic atropine administration on regional vasoactive intestinal polypeptide concentrations in rat brain

J M Petit1, L Denoroy, M Jouvet

  • 1Laboratoire de Médecine Expérimentale, INSERM U52-CNRS URA 1195, Université Claude Bernard, Lyon, France.

European Journal of Pharmacology
|February 25, 1992
PubMed

We studied the effects of 14 days' treatment with atropine sulfate (10 or 20 mg/kg per day) or atropine methyl bromide (20 mg/kg per day) on the concentration of vasoactive intestinal polypeptide like-immunoreactivity (VIP-LI) in the rat brain. VIP-LI in the anterior pituitary as well as brain areas dissected from treated and control rats was measured by radioimmunoassay. VIP-LI in the hypothalamus, and especially in the suprachiasmatic nucleus, was not affected by chronic atropine sulfate administration. Conversely, the same treatment induced a decrease in VIP-LI in the cerebral cortex, dorsal raphe, locus coeruleus, ventrolateral and dorsolateral medulla. In these structures, the decrease in VIP-LI was probably due to muscarinic receptor blockade in the central nervous system rather than in the peripheral nervous system since variations in VIP-LI were not observed after atropine methyl bromide treatment. These findings suggest the existence of a muscarinic control of VIP-LI in discrete brain areas of the rat and particularly in caudal brainstem structures.

More Related Videos

Preparation of Acute Brain Slices Using an Optimized N-Methyl-D-glucamine Protective Recovery Method10:53

Preparation of Acute Brain Slices Using an Optimized N-Methyl-D-glucamine Protective Recovery Method

Published on: February 26, 2018

Autoradiographic Measurements of [14C]-Iodoantipyrine in Rat Brain Following Central Post-Stroke Pain07:27

Autoradiographic Measurements of [14C]-Iodoantipyrine in Rat Brain Following Central Post-Stroke Pain

Published on: July 18, 2016

Related Concept Videos

Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Drugs Acting on Autonomic Ganglia: Stimulants01:23

Drugs Acting on Autonomic Ganglia: Stimulants


Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...